Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff P Sharman

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
Frontiers in Oncology|December 3, 2021
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical PracticeSusan M O'Brien, Jennifer R Brown, John C Byrd, et al.
Leukemia & Lymphoma|November 27, 2020
Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemiaJeff P Sharman, John M Burke, Habte A Yimer, et al.
Leukemia & Lymphoma|January 12, 2019
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 studyFarrukh T Awan, Michael J Thirman, Dipti Patel-Donnelly, et al.
Haematologica|April 21, 2022
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinibAnthony R Mato, Boxiong Tang, Soraya Azmi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2010
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progressionJonathan M Irish, June H Myklebust, Ash A Alizadeh, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2024
Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL RegistryNilanjan Ghosh, Jeff P Sharman, Meghan Gutierrez, et al.
Cancer|June 16, 2004
Gemcitabine-associated thrombotic microangiopathyBenjamin D Humphreys, Jeff P Sharman, Joel M Henderson, et al.
Blood|March 22, 2014
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotinSteven M Horwitz, Ranjana H Advani, Nancy L Bartlett, et al.
Future Oncology (London, England)|September 14, 2022
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphomaChristine E Ryan, Matthew S Davids, Richard Hermann, et al.
Ejhaem|February 23, 2023
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United StatesAnthony Mato, Boxiong Tang, Soraya Azmi, et al.
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Frontiers in Oncology|December 3, 2021
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical PracticeSusan M O'Brien, Jennifer R Brown, John C Byrd, et al.
Leukemia & Lymphoma|November 27, 2020
Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemiaJeff P Sharman, John M Burke, Habte A Yimer, et al.
Leukemia & Lymphoma|January 12, 2019
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 studyFarrukh T Awan, Michael J Thirman, Dipti Patel-Donnelly, et al.
Haematologica|April 21, 2022
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinibAnthony R Mato, Boxiong Tang, Soraya Azmi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2010
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progressionJonathan M Irish, June H Myklebust, Ash A Alizadeh, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2024
Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL RegistryNilanjan Ghosh, Jeff P Sharman, Meghan Gutierrez, et al.
Cancer|June 16, 2004
Gemcitabine-associated thrombotic microangiopathyBenjamin D Humphreys, Jeff P Sharman, Joel M Henderson, et al.
Blood|March 22, 2014
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotinSteven M Horwitz, Ranjana H Advani, Nancy L Bartlett, et al.
Future Oncology (London, England)|September 14, 2022
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphomaChristine E Ryan, Matthew S Davids, Richard Hermann, et al.
Ejhaem|February 23, 2023
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United StatesAnthony Mato, Boxiong Tang, Soraya Azmi, et al.
Pageof 8